List of works - C Kortepeter

Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab.

scientific article published on 30 March 2018

Adverse event detection using the FDA post-marketing drug safety surveillance system: Cardiotoxicity associated with loperamide abuse and misuse.

scientific article

An Evaluation of "Drug Ineffective" Postmarketing Reports in Drug Safety Surveillance.

scientific article

An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System

scientific article published on 24 January 2020

Antipsychotic drugs and venous thromboembolism

Central Nervous System Herpes Simplex and Varicella Zoster Virus Infections in Natalizumab-Treated Patients ⬇️

scientific article published on May 31, 2013

Discontinuation of Direct Oral Anticoagulants in Response to Attorney Advertisements: Data From the FDA Adverse Event Reporting System

scientific article published on 05 May 2019

Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance

scientific article published on 01 May 2019

Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors

article

Hemophagocytic lymphohistiocytosis associated with the use of lamotrigine

scientific article published on 17 April 2019

Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration

scientific article published on 11 October 2019

Labeling and Drug Safety Communication Approaches to Loperamide Abuse

scientific article published on 17 April 2017

Liver injury associated with dimethyl fumarate in multiple sclerosis patients

scientific article published on January 2017

Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.

scientific article

Possible short-term memory loss associated with nafarelin acetate ⬇️

scientific article published on February 1, 1992

Progressive multifocal leukoencephalopathy after natalizumab discontinuation

scientific article published on January 2014

Regarding "Retrograde administration of ultrasound-guided endovenous microfoam chemical ablation for the treatment of superficial venous insufficiency"

scientific article published on 01 March 2019

Reply: Catecholamine-Mediated Pathways in Takotsubo Syndrome: Does it Matter If it Is a Serotonin Norepinephrine Reuptake Inhibitor or a Selective Serotonin Reuptake Inhibitor?

scientific article published on 01 August 2018

Reply: To PMID 24242357

scientific article published on 07 March 2014

Reporting Adverse Events for Cannabis to the FDA

scientific article published on 01 January 2020

Response to: Improvement of sleep architecture parameters in cirrhotic patients with recurrent hepatic encephalopathy with the use of rifaximin: hepatic encephalopathy in association with zolpidem.

scientific article published on 3 May 2017

Takotsubo Common Pathways and SNRI Medications

scientific article published on 01 April 2018

Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility

scientific article published on 01 April 2020

List of works by C Kortepeter

Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab.

Adverse event detection using the FDA post-marketing drug safety surveillance system: Cardiotoxicity associated with loperamide abuse and misuse.

An Evaluation of "Drug Ineffective" Postmarketing Reports in Drug Safety Surveillance.

An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System

Antipsychotic drugs and venous thromboembolism

Central Nervous System Herpes Simplex and Varicella Zoster Virus Infections in Natalizumab-Treated Patients ⬇️

Discontinuation of Direct Oral Anticoagulants in Response to Attorney Advertisements: Data From the FDA Adverse Event Reporting System

Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance

Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors

Hemophagocytic lymphohistiocytosis associated with the use of lamotrigine

Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration

Labeling and Drug Safety Communication Approaches to Loperamide Abuse

Liver injury associated with dimethyl fumarate in multiple sclerosis patients

Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.

Possible short-term memory loss associated with nafarelin acetate ⬇️

Progressive multifocal leukoencephalopathy after natalizumab discontinuation

Regarding "Retrograde administration of ultrasound-guided endovenous microfoam chemical ablation for the treatment of superficial venous insufficiency"

Reply: Catecholamine-Mediated Pathways in Takotsubo Syndrome: Does it Matter If it Is a Serotonin Norepinephrine Reuptake Inhibitor or a Selective Serotonin Reuptake Inhibitor?

Reply: To PMID 24242357

Reporting Adverse Events for Cannabis to the FDA

Response to: Improvement of sleep architecture parameters in cirrhotic patients with recurrent hepatic encephalopathy with the use of rifaximin: hepatic encephalopathy in association with zolpidem.

Takotsubo Common Pathways and SNRI Medications

Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility